Navigation Links
New oncolytic virus shows improved effectiveness in preclinical testing
Date:10/27/2011

COLUMBUS, Ohio A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.

Researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) are developing the oncolytic virus as a treatment for glioblastoma, the most common and deadly form of brain cancer (average survival: 15 months after diagnosis).

The new oncolytic virus, called 34.5ENVE, improved survival of mice with transplanted human glioblastoma tumors by 50 percent in a majority of cases compared with the previous-generation oncolytic virus.

The study was published online in the journal Molecular Therapy.

"These findings show the amazing therapeutic efficacy of this new oncolytic virus against four different glioblastoma models in animals," says cancer researcher Dr. Balveen Kaur, associate professor of neurological surgery, and a member of the OSUCCC James viral oncology research program.

The new oncolytic virus is engineered to replicate in cells that express the protein nestin. First identified as a marker for neuronal stem cells, nestin is also expressed in glioblastoma and other malignancies including gastrointestinal, pancreatic, prostate and breast cancer.

"We believe that nestin-driven oncolytic viruses will prove valuable for the treatment of many types of cancer," Kaur says.

The new oncolytic virus also carries a gene to inhibit tumor blood-vessel growth. That gene, called Vstat120, was added to increase its anti-tumor effectiveness and prolong the virus's presence within tumors.

In this study of eight animals with intracranial tumors, six lived longer than 80 days, and these were later found to be tumor free. By comparison, control mice survived a median of 20 days, and mice
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Oncolytic viruses effectively target and kill pancreatic cancer stem cells
2. BUSM researchers show an oncolytic virus switches off cancer cell survival signal
3. Oncolytic viruses mediating anti-tumor immunity in human cancer patients
4. Oncos Therapeutics raises €4 million ($5.3 million) to develop oncolytic viruses into cancer treatment
5. Veterinary researchers discover first US strains of hepatitis E virus from rabbits
6. Robins Are Super-Spreaders of West Nile Virus, Expert Says
7. Antibody treatment protects monkeys from Hendra virus disease
8. Researchers from Boston University receive grant to develop improved virus detection system
9. Treatment of common virus can reduce tumour growth
10. Could targeting a virus treat a common pediatric brain tumor?
11. UCLA scientists find H1N1 flu virus prevalent in animals in Africa
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/30/2015)... ... August 30, 2015 , ... InHealth Media ( http://www.inhealthmedia.com ... Global Communications Director for InHealth Media. Mr. Spector comes with a wide ... years doing on-air television, producing shows, on air-radio and media relations. , ...
(Date:8/30/2015)... ... August 30, 2015 , ... ... medical devices for the treatment of prostate cancer, has announced the roll-out of ... at the treatment center in Puerto Vallarta, Mexico. , The Sonablate® technology currently ...
(Date:8/29/2015)... ... August 29, 2015 , ... "I have ... Miller Place, N.Y. "I specialize in manual therapy, and my invention will provide ... be used for additional muscle dysfunction throughout the body." , They developed THE ...
(Date:8/29/2015)... ... 2015 , ... Next weekend is Labor Day weekend, the last bash of ... 22nd this year). For IT security personnel, it should also mark the perfect time ... more costly than a simple headache. , Joe Caruso, founder and CEO-CTO of ...
(Date:8/29/2015)... ... 29, 2015 , ... Vascular Health Sciences announced today that ... Arterosil HP, and that all claims and counterclaims have been irrevocably dismissed. , ... in the United States District Court for the Southern District of Texas for ...
Breaking Medicine News(10 mins):Health News:InHealth Media Appoints New Global Communications Director 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4
... ,Genzyme Corporation (Nasdaq: GENZ ) and Bioenvision, ... Bioenvision stockholders have voted to,approve the acquisition of ... meeting in New York. The transaction will be ... the company will,be delisted from Nasdaq. Fifty-six ...
... Vanda Pharmaceuticals,Inc. (Nasdaq: VNDA ) announced today ... of iloperidone at the 57th American Society of ... San Diego, CA, from October 23,through October 27, ... filing for iloperidone on September 27, 2007. Iloperidone ...
... evacuees to register on Safe and Well Website, ... California, forcing thousands to evacuate the area. During this,ongoing ... may feel confused,and anxious about the safety of their ... all those who have evacuated or who expect to,evacuate ...
... A team of Johns Hopkins scientists reports in this weeks ... that humans can be protected against the damaging effects of ... our environment by topical application of an extract of ... by parallel evidence obtained in mice, show that the degree ...
... 22 Shire plc (LSE: SHP,Nasdaq: SHPGY, TSX: ... (ADHD), announced today that it will present key,scientific ... scientific and,educational meeting of child and adolescent psychiatrists ... Shire studies to be presented are indicative of ...
... 22 HealthShares(TM) Inc., an investment,company with a series ... informed by Standard & Poor,s, the calculating agent for ... on,Thursday October 25, 2007, Amag Pharmaceuticals (Nasdaq: AMAG ... the HealthShares(TM) Diagnostics Index, and,Hologic Inc. (Nasdaq: HOLX ...
Cached Medicine News:Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 2Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 3Health News:Bioenvision Shareholders Approve Acquisition by Genzyme Corporation 4Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 2Health News:Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting 3Health News:Southern California Wildfires Continue to Threaten Residential Areas 2Health News:Southern California Wildfires Continue to Threaten Residential Areas 3Health News:Broccoli sprout-derived extract protects against ultraviolet radiation 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 2Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 3Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 4Health News:Shire to Present New Scientific Data on its ADHD Treatments at a Major Psychiatric Meeting 5Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 2Health News:HealthShares(TM) Announces Changes to the HealthShares(TM) Diagnostics and Composite Indexes 3
(Date:8/28/2015)... 2015 Research and Markets ... "Investigation Report on China,s Ranibizumab Market, 2012-2019" ... ranibizumab was approved by CFDA to treat wet age- ... a product of Novartis, is available in the Chinese ... developed drug for the treatment of wet AMD in ...
(Date:8/28/2015)... Aug. 28, 2015 Perrigo Company plc ("Perrigo") ... Mylan N.V. ("Mylan") (NASDAQ: MYL ) shareholder vote ... "Our views of Mylan,s offer to Perrigo shareholders ... on our Board,s careful reflection of the value available ... limited choices that Mylan has allowed its shareholders to ...
(Date:8/28/2015)... HERTFORDSHIRE, England and PITTSBURGH ... (NASDAQ: MYL ) today announced that its ... Company plc (NYSE: PRGO ; TASE) and ... Perrigo,s shareholders at an extraordinary general meeting of ... of two-thirds of the votes cast at the extraordinary general ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9
... COMBINATION WITH DIURETIC ACCEPTED FOR REVIEW BY,FDA- , ... 2007 -,Speedel (SWX: SPPN) today welcomed the significant ... by investigators at the 22nd Annual Scientific Meeting,and ... in,Chicago, IL, USA. These results confirm the favourable ...
... inflammation in models of,arthritis and Salmonella infection, ... -, WASHINGTON, May 21, 2007 /PRNewswire/ -- ... from two studies,that demonstrate the anti-inflammatory activity ... origin, Bifantis(R),(Bifidobacterium infantis 35624), in models of ...
Cached Medicine Technology:New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 2New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 3New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 4New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 5New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 6New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 7New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 8New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 9New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 10New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard,Therapy in Treatment of Hypertension 11New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 2New Data On the Probiotic Strain Bifantis Shows Anti-Inflammatory,Properties and Increased Health Benefits 3
The Doro Halo retractor system is designed for all neurosurgical applications where retraction of the brain tissue and an armrest is required....
Molt 9, excellent for subperiosteal tunneling....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: